Purchase this article with an account.
Katharina Eibenberger, Florian Sulzbacher, Sandra Rezar, Philipp Ken Roberts, Stefan Sacu, Ursula Schmidt-Erfurth; Randomized comparison of anterior chamber inflammatory activity in eyes treated with intravitreal aflibercept or ranibizumab. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1517.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate anterior chamber inflammation in patients with neovascular age-related macular degeneration (AMD) after an intravitreal aflibercept (IVA) or ranibizumab (IVR) treatment.
66 eyes of 50 patients were included in this prospective, comparative, controlled study. 50 eyes randomly received 1:1 either IVA or IVR in eyes with treatment naive neovascular AMD. 16 fellow eyes without any treatment served as a control. Anterior chamber flare was measured with the Kowa FM-500 ® laser flare meter (Kowa Company, Ltd. Tokyo, Japan) at baseline (BSL), one day, one week and one month after treatment. Measurements were expressed in counts/millisecond (counts/ms).
19 men and 31 women (mean age: 77.2±12.1 years) were included. The flare value at baseline was 9.7±6.6 counts/ms in the IVA group (n=25), 8.5±4.2 counts/ms in the IVR (n=25) and 7.4±3.0 counts/ms in the control group. No statistically significant differences were observed (IVA vs. IVR p=0.45; IVA vs. control p=0.20; IVR vs. control p=0.36). At one month, the anterior chamber flare was 9.0±4.5 counts/ms in the IVA group (BSL vs. 1month: p=0.85), 8.9±6.6 counts/ms in the IVR group (BSL vs. 1month: p=0.89) and 7.7±3.8 counts/ms in the control group (BSL vs. 1month: p=0.86).
Intravitreal injection of aflibercept or ranibizumab in neovascular AMD causes no statistically significant ocular inflammatory reaction.
This PDF is available to Subscribers Only